Stay updated on ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page.

Latest updates to the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference2%

- Check27 days agoChange DetectedPage revision updated from v3.0.2 to v3.1.0, indicating a version bump with no other substantive content changes.SummaryDifference0.0%

- Check42 days agoChange DetectedVersion bumped from v3.0.1 to v3.0.2; Back to Top link removed, a minor navigation tweak.SummaryDifference0.1%

- Check49 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.1%

- Check56 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, while key terms related to pharmacological action and various classifications of pembrolizumab have been removed.SummaryDifference0.7%

- Check70 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.0%

Stay in the know with updates to ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page.